Determination of potential long term toxicity of 225Ac-anti-CCR8 mAb including non-tumor tissues which are known to host Tregs (skin, gut) and CCR8+ Tregs (spleen) should be conducted during the pre-clinical phase by treating healthy mice with the escalating doses of 225Ac-anti-CCR8 mAb, observing them for up to 12 months and performing histological analysis of organs for signs of radiation damage. This evidence concerns the gene CCR8 and neoplasm.